Unknown

Dataset Information

0

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.


ABSTRACT: Inhibitors of fibroblast growth factor receptor (FGFR) represent an outstanding treatment approach for selected patients with urothelial cancer (UC). These agents are changing the clinical approach to a subgroup of UC, the luminal-papillary subtype, characterized by FGFR mutations, fusions, or amplification. In this review, we provide an overview of the results of recent clinical trials on FGFR tyrosine kinase inhibitors (TKIs) currently in clinical development for the treatment of UC: erdafitinib, rogaratinib, infigratinib, and the monoclonal antibody vofatamab. The Food and Drug Administration recently granted accelerated approval to erdafitinib for patients with advanced UC with alterations of FGFR2 or FGFR3 after progression on platinum-based chemotherapy. We also look at future therapeutic options of combination regimens with immune-checkpoint inhibitors as strategies for improving the antitumor effects of this class of drug, and for preventing or delaying the development of resistance.

SUBMITTER: Casadei C 

PROVIDER: S-EPMC6878604 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.

Casadei Chiara C   Dizman Nazli N   Schepisi Giuseppe G   Cursano Maria Concetta MC   Basso Umberto U   Santini Daniele D   Pal Sumanta K SK   De Giorgi Ugo U  

Therapeutic advances in medical oncology 20191125


Inhibitors of fibroblast growth factor receptor (FGFR) represent an outstanding treatment approach for selected patients with urothelial cancer (UC). These agents are changing the clinical approach to a subgroup of UC, the luminal-papillary subtype, characterized by FGFR mutations, fusions, or amplification. In this review, we provide an overview of the results of recent clinical trials on FGFR tyrosine kinase inhibitors (TKIs) currently in clinical development for the treatment of UC: erdafitin  ...[more]

Similar Datasets

| S-EPMC8151905 | biostudies-literature
| S-EPMC4142045 | biostudies-literature
| S-EPMC8507635 | biostudies-literature
| S-EPMC10814066 | biostudies-literature
| S-EPMC7133705 | biostudies-literature
| S-EPMC10362036 | biostudies-literature
| S-EPMC7257776 | biostudies-literature
| S-EPMC4445091 | biostudies-literature
| S-EPMC4648175 | biostudies-other
| S-EPMC7533235 | biostudies-literature